Olivier Van Der Meeren

Author

GlaxoSmithKline (Belgium)ORCID

Also Known As

O Van Der Meeren, O. Van Der Meeren, Olivier Van Der Meeren, Olivier Van der Meeren

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (Belgium)GlaxoSmithKline (India)University of Cape Town South African Medical Research Council Aurum Institute

About

Olivier Van Der Meeren is an author at GlaxoSmithKline (Belgium) specializing in medicine, vaccination, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	252
2	Immunology	8	8	252
3	Allergy	3	3	122
4	Humoral Immunity	2	2	31
5	Public Health	1	1	95

Olivier Van Der Meeren

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Final Analysis of a Trial of M72/AS01 <sub>E</sub> Vaccine to Prevent Tuberculosis Dereck Tait, Mark Hatherill, Olivier Van Der Meeren, New England Journal of Medicine	2019	561
Phase 2b Controlled Trial of M72/AS01 <sub>E</sub> Vaccine to Prevent Tuberculosis Olivier Van Der Meeren, Mark Hatherill, Videlis Nduba, New England Journal of Medicine	2018	392
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults Glenda Gray, Linda‐Gail Bekker, Fatima Laher, New England Journal of Medicine	2021	221
Decennial Administration of a Reduced Antigen Content Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine in Young Adults Jussi Mertsola, Olivier Van Der Meeren, Qiushui He, Clinical Infectious Diseases	2010	96
Effect of a Prepregnancy Pertussis Booster Dose on Maternal Antibody Titers in Young Infants Elke Leuridan, Niel Hens, Natasja Peeters, The Pediatric Infectious Disease Journal VaccinationMaternal Antibody TitersMaternal ImmunizationAllergyVaccine Development	2011	95
Long-term antibody persistence after vaccination with a 2-dose Havrix™ (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions Heidi Theeten, Koen Van Herck, Olivier Van Der Meeren, Vaccine	2015	80
A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix™) is immunogenic and well tolerated in adults Robert Booy, Olivier Van Der Meeren, Su-Peing Ng, Vaccine VaccinologyVaccine SafetyVaccinationVaccine DevelopmentImmunodeficiencies	2010	64
Persistence of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine Pierre Van Damme, Geert Leroux‐Roels, P.V. Suryakiran, Human Vaccines & Immunotherapeutics	2017	50
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines Fatima Laher, Zoe Moodie, Kristen W. Cohen, PLoS Medicine	2020	48
Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults Nagalingeswaran Kumarasamy, Selvamuthu Poongulali, Faith Esther Beulah, Medicine	2018	46

Page 1